Trials / Completed
CompletedNCT02236312
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Three Doses of Botulinum Toxin in the Treatment of Moderate to Very Severe Glabellar Frown Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 359 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the efficacy in wrinkle reduction of a single treatment of three different doses of botulinum toxin compared to placebo, in the treatment of moderate to very severe glabellar frown lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum Toxin Type A | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2014-11-01
- Completion
- 2015-05-01
- First posted
- 2014-09-10
- Last updated
- 2022-08-26
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02236312. Inclusion in this directory is not an endorsement.